Research Explorer

Project

Development of a vaccine against Rift Valley fever virus
Code
42M01219
Duration
01 January 2019 → 31 December 2023
Funding
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Infectious diseases
Keywords
vaccine
 
Project description
 

A consortium of six partners has a single goal: the development and evaluation of a vaccine for the prevention of Rift Valley fever in humans. The project is named "LARISSA", acronym for Live Attenuated Rift Valley Fever Vaccine for Single Shot Application. ​​​LARISSA will manufacture and validate a vaccine for the prevention of Rift Valley fever in humans. The project encompasses vaccine manufacturing, preclinical research, and a Phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose of the vaccine.

​